A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to prove and confirm the efficacy and safety of multiple injections of human recombinant vascular endothelial growth factor receptor-Fc fusion protein (KH902) in patients with choroidal neovascularization due to neovascular age-related macular degeneration by comparing intravitreal injections of KH902 with sham-injections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD

NCT01242254

Neovascular Age-related Macular Degeneration

COMPLETED PHASE1/PHASE2

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

NCT03387566

Neovascular Age-Related Macular Degeneration

COMPLETED PHASE1

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

NCT04270669

Wet Age-Related Macular Degeneration

COMPLETED PHASE1/PHASE2

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

NCT06888492

NOT_YET_RECRUITING EARLY_PHASE1

A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

NCT01157715

Neovascular Age-related Macular Degeneration

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is the main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost.

The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase II study showed that KH902 is well-tolerated,and safe, it is effective in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.

This study is designed to prove and confirm the efficacy and safety of multiple injections of KH902 in patients with choroidal neovascularization due to neovascular age-related macular degeneration by comparing intravitreal injections of KH902 with sham-injections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.5 mg KH902

Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)

Group Type EXPERIMENTAL

Recombinant Human VEGF Receptor-Fc Fusion Protein

Intervention Type BIOLOGICAL

Intravitreal injection of KH902 once per month

Sham-injection

Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.

Group Type SHAM_COMPARATOR

Recombinant Human VEGF Receptor-Fc Fusion Protein

Intervention Type BIOLOGICAL

Intravitreal injection of KH902 once per month

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant Human VEGF Receptor-Fc Fusion Protein

Intravitreal injection of KH902 once per month

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed the Informed Consent Form;
* Age ≥ 50 years of either gender;
* Total lesion size ≤ 30 mm2 of the study eye;
* BCVA score of the study eye between 73 and 19 letters;
* Clear ocular media and adequate pupil dilation to permit good quality fundus photographic imaging.
* BCVA score of the fellow eye ≥ 19 letters.

Exclusion Criteria

* Current or previous non-exudative AMD diseases which affect the inspection and measurement of macular or the central visual acuity;
* Subretinal hemorrhage area≥ 50% of total lesion size;
* Scar or fibrosis area in study eyes ≥ 50% of total lesion size; or central foveal scar、fibrosis or atrophy of macular in the study eye;
* Presence of retinal pigment epithelial tear, retinal macular tractional, macular epiretinal membrane, and diagnosed with polypoidal choroidal vasculopathy in the study eye;
* Previous anti-VEGF drug treatment in the study eye within six months preceding screening; or anti-VEGF treatment in the fellow eye within three months before screening;
* Previous intraocular or periocular operations, excluding operations on eyelid without hampering the intravitreal injection in the study eye;
* Previous ophthalmologic operations in the study eye;
* Current active inflammation or infection in either eye;
* Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye;
* Current systemic administrations which may lead to toxicity in the crystalline lens;
* History of allergy or current allergic response;
* History of surgery within one month preceding enrollment;
* Infectious diseases need systemic administration;
* Systemic autoimmune diseases;
* Any uncontrolled clinical disorders;
* Patients of child-bearing potential do not adopted adequate contraception methods;
* Pregnant or nursing women;
* Patients should be excluded in the opinion of investigators;

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No